Targeting Mucus Hypersecretion: New Therapeutic Opportunities for COPD?
- 3 June 2014
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 74 (10) , 1073-1089
Abstract
Airway mucus has a key role in protective innate immune responses, but excessive mucus production and secretion in proximal and in distal airways are associated with disabling symptoms (cough and sputum), lung function decline, exacerbations and mortality in patients with chronic obstructive pulmonary disease (COPD). Cellular and molecular mechanisms leading to mucin production and secretion have largely been identified using cultured epithelial cells and animal models. Cigarette smoke and microbial products are potent triggers of mucin production, which involves recognition of specific molecular patterns by cognate receptors and activation of metalloproteases at the epithelial cell surface, leading to epidermal growth factor receptor activation and mucin mRNA and protein synthesis. After mucin synthesis has occurred, mucins are tightly packed into intracytoplasmic granules. Many stimuli induce secretion of mucin granules from epithelial cells, but neutrophil serine proteases are the most potent inducers of mucin secretion. Neutrophils recruited to the airway epithelium also promote mucin production via neutrophil proteases and oxidative stress. Several drugs currently available for the treatment of COPD patients reduced mucus hypersecretion in preclinical models relevant to COPD, but their effects on mucus hypersecretion in humans have not been assessed. Testing the effects of these drugs and of novel molecules designed for reducing mucus production and/or secretion will require performing specifically designed clinical trials. These trials will be necessary to explore the hypothesis that reducing mucus hypersecretion is beneficial in COPD patients.Keywords
This publication has 152 references indexed in Scilit:
- Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungsProceedings of the National Academy of Sciences, 2012
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epitheliumAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Macrolide Antibiotics Inhibit Mucus Secretion and Calcium Entry in Swine Airway Submucosal Mucous Gland CellsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- MARCKS-related peptide modulates in vivo the secretion of airway Muc5acAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Structure and Function of the Polymeric Mucins in Airways MucusAnnual Review of Physiology, 2008
- Regulated Airway Goblet Cell Mucin SecretionAnnual Review of Physiology, 2008
- Cigarette smoke increases Toll‐like receptor 4 and modifies lipopolysaccharide‐mediated responses in airway epithelial cellsImmunology, 2008
- Macrolides attenuate mucus hypersecretion in rat airways through inactivation of NF‐κBRespirology, 2008